Roche reports first half earnings

Roche (SWX:ROCZ) reported CHF 14.6 billion ($11.9 billion) in first half sales from continuing operations, up 14% (in local currencies) from the same period last year. Prescription drug sales increased 16% to CHF 10.6 billion ($8.7 billion). HCV drugs Pegasys peginterferon alfa-2a and Copegus ribavirin posted combined sales of CHF 783 million ($639.5 million). Also, ROCZ submitted an sBLA to FDA and an MAA to the EMEA for Pegasys peginterferon alfa-2a to treat chronic HBV. ...